Alector fell on its trading debut but raised ... plan that is keeping the US government open is set to expire. Gossamer Bio and Harpoon Therapeutics are expected to list in the coming days ...

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to ...

Alector said AbbVie remains on board with AL002 ... web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology. The ESG in Life Sciences ...

The agreement announced Monday gives GSK access to a platform technology developed by ABL Bio. Specific diseases ... programs from a partnership with Alector that began 2021.

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock ...

March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

Alector (ALEC) announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in ...

HC Wainwright reaffirmed their buy rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research note released on Thursday morning,Benzinga reports. They currently have a $7.00 target ...